Pharmaceutical Technology, JanuaryFebruary 2025

Application of AI/ML technology and a burst of M&A activity look to be shaping the future of the pharma industry.

Survey results show that being intellectually stimulated and getting assigned challenging projects are two key drivers of employee satisfaction, yet job training is lacking.

European biopharma companies are looking beyond GLP-1s.

Increasing API and formulation complexity and new delivery strategies are driving innovations in taste-masking.

Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.

Process consistency and robustness, analytical excellence, and regulatory compliance are essential in the scale-up of biosimilars.

Developers save money and time while accessing expertise.

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

CDMOs who have integrated technologies can help further the advancement of ADC development.

EMA introduced its New Fee Regulation in January 2025, but what impact will the new fees and charges have on medicine developers?

Bio/pharma companies have a lot to consider when tackling social media communications, especially within Europe.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.